LNA Sante SA (LNA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of LNA Sante SA stock €45.47, price €26.40, upside +72.2%, quality 54 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range €16.13 – €48.18 · fair‑value band €38.69 – €64.48 · the €26.40 price screens below the €45.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.
Follow LNA Sante in your weekly email
Every Wednesday you see whether LNA Sante is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
LNA Santé SA engages in the management and operation of healthcare facilities and medical residences for able-bodied, semi-dependent, or dependent elderly people in France. The company operates medical care and rehabilitation units; mental health clinics; health centres; and care homes.
Show moreShow less
It also provides respiratory assistance and rehabilitation, cancerology, diabetology, pain management, therapeutic education for the patient and his/her family, geriatrics, enteral and parenteral nutrition, obstetrics, antenatal and postnatal, complex dressings and specific care, post-operative care, anti-cancer chemotherapy, post-chemotherapy, radiotherapy and aplasia monitoring, psychological or social care, neurological and orthopedic rehabilitation, palliative care, intensive nursing care, intravenous treatment/infusion, blood transfusion, education for the patient and his/her loved ones, paracentesis, pleural or peritoneal drainage, and other treatment services.
In addition, the company offers general, ENT carcinological, digestive and urology, dental, spinal, cosmetic, gynecological and obstetric, maxillo-facial, eye, ENT, orthopedic and trauma, plastic and cosmetic facial, stomatological, urological, vascular, and visceral and digestive surgery, as well as digestive endoscopies and hepato-gastroenterology services.
LNA Santé SA was founded in 1990 and is based in Vertou, France.
Stock analysis
LNA Sante SA (LNA) currently trades at €26.40, while our model-based Fair Value estimate is €45.47, implying the stock looks roughly 42% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of €95.73 per share, and 18 of the 24 models we run sit above the €26.40 price.
Bear case: the Dividend Discount group reads lowest at €7.95, and 6 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: €38.69 (bear) to €64.48 (bull), the price of €26.40 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
LNA Sante SA reported revenue of €913M in FY2025 versus €689M in FY2021, a compound +7.3%/yr. Reported net income was €24.1M in FY2025, compounding +0.7%/yr from FY2021.
Key figures
Market cap €272M Small · P/E ratio 10.7 · P/S ratio 0.29 · EPS (TTM) €2.47 · Dividend yield 3.6% · Net margin 2.7% · Return on equity 8.0% · Return on assets (EBIT) 4.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 72%, LNA screens cheaper than that median.
Fair Value models
Bear€38.69Fair Value €45.47Bull€64.48
Price €26.40 · Upside +72.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€1.30 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.75/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Start year 2020 (pandemic). Over 10 years: +7.9% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.7%
Dividend (yield on the price)3.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.7% vs 6.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 8%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +0.2% a year for the price and +3.7% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside+72.2% · Top 25%
Profitability
Return on equity (12 months)8.0% · Below median
Return on assets1.5% · Below median
Net margin (12 months)2.7% · Below median
Operating margin (12 months)7.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)8.4% · Above median
Dividend yield (12 months)3.6% · Above median
Balance sheet
Debt / equity0.90× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)10.7× · Cheapest 25%
P/B0.82× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "LNA Sante SA Fair Value". https://www.fairvalue-calculator.com/stock/LNA
Frequently asked questions
Is LNA Sante SA (LNA) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of €45.47 versus a price of €26.40, about +72% upside (undervalued).
What is the fair value of LNA?
Our model-based fair value for LNA Sante SA is €45.47 (as of Nov 8, 2026), built from audited fundamentals. The current price: €26.40.
What is the quality score of LNA?
LNA Sante SA has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LNA Sante SA (LNA)?
Our model-based price target is the fair value of €45.47 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario €38.69, optimistic scenario €64.48. It is a calculation from audited fundamentals, not an analyst target.
What is the LNA Sante SA stock forecast for 2026?
Our models put fair value at €45.47, about +72% upside versus a price of €26.40 (undervalued). Cautious scenario €38.69, optimistic scenario €64.48. The calculation is refreshed regularly with new filings.
What is the revenue of LNA Sante SA (LNA)?
LNA Sante SA reported trailing-twelve-month revenue of about €950M (latest available figure, as of Nov 8, 2026).
Does LNA Sante SA pay a dividend?
LNA Sante SA currently shows a dividend yield of 3.60% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of LNA Sante SA (LNA) and when is the ex-dividend date?
LNA Sante SA pays a dividend of €0.95 per share a year, a dividend yield of 3.6%. The last ex-dividend date was Jul 8, 2026. A dividend has been paid every year since at least 2016. The payout ratio is 38.5% of earnings. Free cash flow covers the dividend 6.06 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into LNA Sante SA (LNA)?
For today's price to be fair in a discounted-cash-flow model, LNA Sante SA would have to grow free cash flow by +2.4 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of LNA use?
Our models discount LNA Sante SA at 11.8 %: a base by market capitalisation (micro), damped by beta 0.52, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For LNA Sante SA that is +2.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has LNA Sante SA (LNA) delivered so far?
Over the past 5 years revenue at LNA Sante SA grew +9.7 % a year. The price currently implies free-cash-flow growth of +2.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of LNA Sante SA (LNA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into LNA Sante SA (+2.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of LNA Sante SA (LNA)?
The free-cash-flow yield on the price is 21.82 %: that much free cash flow LNA Sante SA produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of LNA Sante SA (LNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LNA Sante SA it is €45.47 per share (as of Nov 8, 2026), against a price of €26.40. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is LNA Sante SA stock overvalued or undervalued in 2026?
As of Nov 8, 2026, LNA trades below its calculated fair value: price €26.40, fair value €45.47, a gap of about +72% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LNA?
No. The price is what the market pays today (€26.40); the fair value is what the company's own numbers justify (€45.47). For LNA Sante SA the two are €19.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is LNA Sante SA worth?
The market values LNA Sante SA at about €272M (market capitalisation, as of Nov 8, 2026). Per share that is €26.40; our models calculate a fair value of €45.47 per share.
What do the bullish and bearish scenarios say about LNA?
Our models span a range for LNA Sante SA: cautious scenario €38.69, base €45.47, optimistic €64.48 per share (as of Nov 8, 2026, price €26.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LNA?
LNA Sante SA trades at a price-to-earnings ratio of 10.7 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €45.47 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 17.2. Other multiples: PEG 1.2, P/B 0.8, P/S 0.3, EV/EBITDA 4.8.
What is the PEG ratio of LNA?
The PEG ratio of LNA Sante SA is 1.16 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of LNA Sante SA (LNA)?
Balance-sheet figures for LNA Sante SA (as of Nov 8, 2026): return on equity 8.0%, debt of 0.90 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is LNA from its 52-week high?
LNA Sante SA trades at €26.40, about 27% below its 52-week high of €36.10 and 18% above the low of €22.30 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €45.47 is for.
Which stocks are comparable to LNA Sante SA?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LNA Sante SA stock attractive at the current price?
The data as of Nov 8, 2026: price €26.40, calculated fair value €45.47 (+72%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LNA calculated?
We run LNA Sante SA through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €45.47 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. LNA Sante SA currently trades 42% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LNA Sante SA (LNA)?
The closing price on Nov 6, 2026 was €26.40. Our model-based fair value is €45.47, about +72% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LNA Sante SA right now?
The price is below even our cautious bear case (€38.69). The market is more pessimistic than our downside scenario. Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of LNA Sante SA (LNA) come from?
Earnings per share at LNA Sante SA grew +4.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.7 %, EBIT margin +1.9 %, tax rate −0.8 %, residual (interest, one-offs) −2.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of LNA Sante SA
How large is the market capitalisation of LNA Sante SA (LNA)?
The market capitalisation of LNA Sante SA is €272M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LNA Sante SA (LNA)?
The price-to-sales ratio of LNA Sante SA is 0.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LNA Sante SA (LNA)?
Earnings per share at LNA Sante SA are €2.47 (price ÷ EPS = P/E 10.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of LNA Sante SA (LNA)?
The dividend yield of LNA Sante SA is 3.6% (payout 38.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of LNA Sante SA (LNA)?
The net margin of LNA Sante SA is 2.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LNA Sante SA (LNA)?
The return on equity (ROE) of LNA Sante SA is 8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LNA Sante SA (LNA)?
On an EBIT basis the return on assets of LNA Sante SA is 4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LNA Sante SA (LNA)?
The operating margin of LNA Sante SA is 7.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LNA Sante SA (LNA)?
Revenue at LNA Sante SA is growing +8.4% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LNA Sante SA (LNA)?
Earnings per share at LNA Sante SA are growing +10.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does LNA Sante SA (LNA) carry?
The net debt of LNA Sante SA is €812M (fiscal year 2025, ≈ 13.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch LNA Sante SA in the live analysis
One click puts LNA Sante SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026